ÂÜÀòÂÒÂ×

Hilary Eaton, PhD, currently serves as the Chief Business Officer at Profluent, a position held since February 2024. Prior to this, Eaton held the role of Senior Vice President and Head of Business Development at Tome Biosciences from January 2022 to June 2023, leading a team in various aspects of business development and program management. Previously, Eaton was the Head of Business Development at Vor Biopharma and held multiple positions at Editas Medicine, where significant transactions were executed. Early career experiences include roles at the Belfer Office for Dana-Farber Innovations, and a postdoctoral fellowship at Harvard Medical School. Eaton earned a PhD in Molecular Cancer Biology from Duke University and holds dual bachelor's degrees in Spanish and Zoology from Michigan State University.